DOCSLIB.ORG

Approaches to Improving Embryo Implantation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

APPROACHES TO IMPROVING EMBRYO IMPLANTATION by JUSTIN JAMIE CHU A thesis submitted to the University of Birmingham for the degree of DOCTOR OF PHILOSOPHY School of Clinical and Experimental Medicine, College of Medical and Dental Science, University of Birmingham, May 2016 University of Birmingham Research Archive e-theses repository This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property rights of the author or third parties in respect of this work are as defined by The Copyright Designs and Patents Act 1988 or as modified by any successor legislation. Any use made of information contained in this thesis/dissertation must be in accordance with that legislation and must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the permission of the copyright holder. Abstract Embryo implantation represents a complex process vital in ensuring the normal development of pregnancy. Whether embryo implantation is the goal of natural conception or assisted reproductive treatment, the environment within the uterine cavity must be optimised in order to increase the chance of pregnancy. This thesis uses a mixture of research methods to investigate potential approaches to improving embryo implantation. Below are the key findings from this thesis: 1. The vitamin D status in women undergoing assisted reproductive treatment is important. An interventional trial would prove or disprove the merits of vitamin D deficiency treatment in these women. 2. There is not enough evidence to suggest a clear association between vitamin D and recurrent miscarriage, however there is a strong argument for biological plausibility. 3. The use of endometrial fluid collected at the time of embryo transfer in women undergoing assisted reproductive treatments for metabolomics analysis is possible. 4. Women with hydrosalpinx associated tubal infertility should be offered salpingostomy as a treatment option as the natural conception rates are similar to that achieved in in vitro fertilisation treatment. i Dedication I would like to dedicate this thesis to Anneke, Lily and Rolo – my wife, daughter and labradoodle who give me the greatest joy and happiness. I also dedicate this thesis to my parents, Paul and Sylvia Denham, who have supported me throughout my career and have been there for me in good times and in bad. ii Acknowledgments I wish to issue great thanks to Professor Arri Coomarasamy, who has been my supervisor, mentor and friend throughout my journey so far in medical research. I thank Ioannis Gallos for guiding me through my statistical analyses and enhancing my knowledge of research methodology. I also wish to thank Jackson Kirkman-Brown for his supervision and mentorship in the endometrial fluid metabolomics chapters included in this thesis. Thank you to Warwick Dunn and his metabolomics team at the University of Birmingham for the assistance and guidance with the endometrial fluid metabolomics work. I would like to acknowledge the kind team at the Birmingham Women’s Fertility Centre for allowing me to recruit patients and collect samples there. Thank you to Bee Tan, Abey Eapen and Hoda Harb who acted as second reviewers for the systematic reviews. Thank you to Rima Smith and Hoda Harb for helping with recruitment of patients into my cohort studies. Lastly, I would like to thank all of the patients that consented to participation in my studies. iii Abbreviations 1,25[OH]2D 1,25-dihydroxyvitamin D / Calcitriol 25[OH]D 25-hydroxyvitamin D / Calcidiol ART Artificial Reproductive Treatment BMI Body Mass Index CCG Clinical Commissioning Group ChRS Centre of Human Reproductive Sciences CI Confidence Interval CSF2 Colony Stimulating Factor-2 DIMS Direct Infusion Mass Spectrometry FET Frozen Embryo Transfer HFEA Human Fertility and Embryology Authority HOX10A Homeobox-leucine zipper protein 10 A ICSI Intra-cytoplasmic Sperm Injection IF-ϒ Interferon gamma IL Interleukin IQR Interquartile Range IVF In Vitro Fertilisation LC-MS/MS Tandem Liquid Chromatography Mass Spectrometry LIF Leukaemia Inhibiting Factor MeSH Medical Subject Heading NHS National Health Service NICE National Institute for Health and Care Excellence NRES National Research Ethics Service PCOS Polycystic Ovarian Syndrome PID Pelvic Inflammatory Disease SD Standard Deviation TNF-α Tumour Necrosis Factor-alpha TGF-β Transforming Growth Factor Beta iv UK United Kingdom VDBP Vitamin D Binding Protein v Contents APPROACHES TO IMPROVING EMBRYO IMPLANTATION ........................................................... i Abstract ....................................................................................................................................... i Dedication ................................................................................................................................... ii Acknowledgments ..................................................................................................................... iii Abbreviations ............................................................................................................................. iv List of Tables ............................................................................................................................ xiv List of Figures ............................................................................................................................ xv CHAPTER 1: THESIS INTRODUCTION .......................................................................................... 1 Embryo implantation .............................................................................................................. 2 Entry of the morula into the endometrial cavity ............................................................... 2 Blastocyst adherence and penetration .............................................................................. 3 The importance of the endometrium in embryo implantation ............................................. 5 Infertility as a disease ............................................................................................................. 7 Causes of infertility ................................................................................................................. 7 Treatment of infertility ........................................................................................................... 8 Fertility treatment funding ................................................................................................... 10 IVF and embryo implantation ............................................................................................... 10 Vitamin D and IVF treatment ................................................................................................ 12 Vitamin D and recurrent miscarriage ................................................................................... 13 vi The use of endometrial fluid in predicting IVF treatment outcome .................................... 13 Salpingostomy in the treatment of hydrosalpinx ................................................................. 15 Conclusions drawn ................................................................................................................ 16 CHAPTER 2: VITAMIN D AND ASSISTED REPRODUCTIVE TREATMENTS – SYSTEMATIC REVIEW AND META-ANALYSIS................................................................................................................ 17 Introduction .......................................................................................................................... 18 Methods................................................................................................................................ 21 Literature Search .............................................................................................................. 21 Study Selection ................................................................................................................. 22 Validity Assessment .......................................................................................................... 23 Statistical Analysis ............................................................................................................ 23 Results................................................................................................................................... 24 Study characteristics ......................................................................................................... 26 Clinical pregnancy ............................................................................................................. 35 Clinical pregnancy rates according to source of oocyte used .......................................... 37 Clinical pregnancy rates according to biofluid used to assess vitamin D status .............. 40 Live birth ........................................................................................................................... 40 Implantation ..................................................................................................................... 41 Miscarriage ....................................................................................................................... 44 Discussion ............................................................................................................................. 46 vii Summary ..............................................................................................................................
Recommended publications
  • 20. Riesgos Y Complicaciones En FIV-ICSI

    20. Riesgos Y Complicaciones En FIV-ICSI

    01 serono 1-6 OK:Maquetación 1 8/3/07 12:14 Página 223 20. Riesgos y complicaciones en FIV-ICSI RIESGOS DERIVADOS DEL TRATAMIENTO HORMONAL Estimulación ovárica y riesgo de cáncer La medicación para estimular la ovulación se utiliza desde hace unos cuarenta años para tratar la infertilidad. En los últimos veinte años, diferentes estudios empiezan a cuestio- nar la seguridad de estos fármacos y su relación con distintos tipos de cáncer. Ayhan y cols. en una revisión en el año 2004, concluyen que se necesitan estudios prospectivos, multicéntricos y durante largos periodos de tiempo para determinar la relación entre el uso de los fármacos para estimular la ovulación y el riesgo de cáncer(1). En el año 2000, Klip et al. realizan una revisión desde 1966 a 1999 donde se analiza la relación entre el uso de fármacos de estimulación ovárica y el riesgo de cáncer de ova- rio, mama, endometrio, tiroides y melanoma. Aunque se sugiere una relación entre el uso de los fármacos y el riesgo de cáncer, no existen estudios epidemiológicos que lo demues- tren(2). Más tarde, Kashyap et al. 2004, en su metaanálisis, demuestran una tendencia hacia un efecto beneficioso de las técnicas de reproducción asistida, ya que suelen fina- lizar en embarazo, que es un factor protector contra el cáncer de ovario(3). Sin embargo, Ness et al., 2002, publicaron un metaanálisis(4), en el que encontraban un ligero aumento de riesgo de neoplasia borderline en pacientes que habían sido expues- tas a tratamientos de infertilidad, cuando se comparaba con la población normal, pero Mosgaard demostró que ello es debido en parte a la propia infertilidad(5).
  • The ART of Assisted Reproductive Technology

    The ART of Assisted Reproductive Technology

    Infertility • THEME The ART of assisted reproductive technology BACKGROUND One in six Australian couples of The Australian Institute of Health and Welfare's reproductive age experience difficulties in National Perinatal Statistical Unit's annual report Jeffrey Persson, conceiving a child. Once a couple has been Assisted reproductive technology in Australia and New MD, FRANZCOG, CREI, is Clinical appropriately assessed, assisted reproductive Zealand 2002, shows that babies born in 2002 using Director (City), technology (ART) techniques can be used to assisted reproductive technology (ART) had longer IVFAustralia. overcome problems with ovulation, tubal patency, gestational ages, higher birth weights and fewer peri- [email protected] male fertility or unexplained infertility. natal deaths than their counterparts of 2 years OBJECTIVE This article discusses the range of previously.1 ART techniques available to subfertile couples. This is the first year national data have been avail- able on the age of women (and their partners) using DISCUSSION Intracytoplasmic sperm injection is now the most common form of ART used in ART. The average age of women undergoing treat- Australia, being used in almost half of all fresh ment in 2002 was 35.2 years, and the average cycles, with in vitro fertilisation being used in age of partners was 37.6 years.1 Age remains the approximately one-third of all fresh cycles. most significant issue affecting a couple's chance of conceiving and carrying a pregnancy to full term. Women need to understand the impact age has on their chance of becoming pregnant. Once a couple has been assessed and investigations suggest subfer- tility, the treatment options depend on the underlying cause (Table 1).
  • Secretome Identification of Immune Cell Factors Mediating Metastatic Cell Homing Received: 07 September 2015 1,2 3 4 5 6 Accepted: 02 November 2015 Brian A

    Secretome Identification of Immune Cell Factors Mediating Metastatic Cell Homing Received: 07 September 2015 1,2 3 4 5 6 Accepted: 02 November 2015 Brian A

    www.nature.com/scientificreports OPEN Secretome identification of immune cell factors mediating metastatic cell homing Received: 07 September 2015 1,2 3 4 5 6 Accepted: 02 November 2015 Brian A. Aguado , Jia J. Wu , Samira M. Azarin , Dhaval Nanavati , Shreyas S. Rao , 7 8 7,9,10 Published: 04 December 2015 Grace G. Bushnell , Chaitanya B. Medicherla & Lonnie D. Shea Metastatic cell homing is a complex process mediated in part by diffusible factors secreted from immune cells found at a pre-metastatic niche. We report on connecting secretomics and TRanscriptional Activity CEll aRray (TRACER) data to identify functional paracrine interactions between immune cells and metastatic cells as novel mediators of homing. Metastatic breast cancer mouse models were used to generate a diseased splenocyte conditioned media (D-SCM) containing immune cell secreted factors. MDA-MB-231 metastatic cell activity including cell invasion, migration, transendothelial migration, and proliferation were increased in D-SCM relative to control media. Our D-SCM secretome analysis yielded 144 secreted factor candidates that contribute to increased metastatic cell activity. The functional mediators of homing were identified using MetaCore software to determine interactions between the immune cell secretome and the TRACER-identified active transcription factors within metastatic cells. Among the 5 candidate homing factors identified, haptoglobin was selected and validated in vitro and in vivo as a key mediator of homing. Our studies demonstrate a novel systems biology approach to identify functional signaling factors associated with a cellular phenotype, which provides an enabling tool that complements large-scale protein identification provided by proteomics. During cancer progression, the likelihood of patient survival significantly declines with the formation of metastatic tumors.
  • Scientific Programme 30 April

    Scientific Programme 30 April

    Scientific Programme 30 April - 3 May 2014 Adding pieces to the puzzle of endometriosis Contents 16.00 to 18.30 Sponsors 4 Welcome 5 Partner organisations 8 WES and committees 9 Venue plan 10 At a glance programme 12 Pre-congress courses Wednesday 14 Opening ceremony 19 Programme Thursday 20 Programme Friday 24 Programme Saturday 28 Closing ceremony 31 Exhibitor / poster floor plan 32 Sponsor profiles 33 List of presenters 36 Local information 42 The organisers of WCE2014 would like to thank our generous sponsors Diamond Gold Ruby Silver Bronze Supported by 4 Welcome Dear Colleagues and Friends, Welcome to São Paulo and to the 12th World Congress on Endometriosis. The theme of WCE2014, “Adding pieces to the puzzle of endometriosis”, has been chosen because we Maurício Simões Abrão, are currently experiencing a rapid advancement of new technologies for the diagnosis and management WCE2014 President of endometriosis and, with that, improvements in our understanding of the disease. At the heart of every congress is the scientific programme, which keeps the momentum of our advancements in endometriosis alive through a robust exchange of ideas among the experts and learners in the field. We have received more than 500 outstanding abstracts from the international community, and have put together an extensive and in-depth programme featuring more than 150 speakers and close to 300 poster presentations spanning almost every topic you can imagine that has relevance to endometriosis. This is truly the world event on endometriosis and I welcome each and every one of you to São Paulo to be part of this clinical and scientific extravaganza! For me it is an exciting time to welcome you to São Paulo, one of the top international capitals for gastronomy, architecture and design, cultural heritage and music.
  • In Vitro Fertilisation and Embryo Research

    In Vitro Fertilisation and Embryo Research

    Briefing Note INFORMATION FOR MEMBERS FROM THE 6 Parliamentary Office of Science and Technology November 1989 Figure 1.. Conceptus after 15 days In Vitro Fertilisation and Embryo Research Actual size Following the Warnock Report of 1984 and the 1987 White Paper, the Government has introduced the Human Fertilisation and Embryology Bill con­ taining provisions on research involving human embryos. Parliament is asked to decide between two options set out in Section 11 of the Bill which determine whether the Human Fertilisation and Embryology Authority(HFEA) is empowered to grant licences for research involving human embryos less than 14 days old. This question involves substantial ethical and religious considerations. An understanding of scientific aspects of human fertilisation and embryology may assist Parliamentarians to come to grips with these considerations. Some of the relevant science and technology is de­ scribed in this note. it is argued that this should not be such as to prevent the benefits to others which research may provide. THE STATUS OF THE EARLY EMBRYO Science alone cannot resolve this question, but a clearer understanding of the early developmental process of An important issue relates to the status afforded the the fertilised egg may provide illumination to allow in­ fertilised egg and the early (pre-14 day) embryo or dividuals to reach their own decision. conceptus1. Some argue that these should have the status of a human being from the moment of fertilisa­ Early Human Development tion, since the fusion of egg and sperm produces a unique genetic combination which, if it develops nor­ After the egg has been fertilised, it divides into two mally, will develop into a child.
  • The Protection of the Human Embryo in Vitro

    The Protection of the Human Embryo in Vitro

    Strasbourg, 19 June 2003 CDBI-CO-GT3 (2003) 13 STEERING COMMITTEE ON BIOETHICS (CDBI) THE PROTECTION OF THE HUMAN EMBRYO IN VITRO Report by the Working Party on the Protection of the Human Embryo and Fetus (CDBI-CO-GT3) Table of contents I. General introduction on the context and objectives of the report ............................................... 3 II. General concepts............................................................................................................................... 4 A. Biology of development ....................................................................................................................... 4 B. Philosophical views on the “nature” and status of the embryo............................................................ 4 C. The protection of the embryo............................................................................................................... 8 D. Commercialisation of the embryo and its parts ................................................................................... 9 E. The destiny of the embryo ................................................................................................................... 9 F. “Freedom of procreation” and instrumentalisation of women............................................................10 III. In vitro fertilisation (IVF).................................................................................................................. 12 A. Presentation of the procedure ...........................................................................................................12
  • (IVF/ICSI) Treatment

    (IVF/ICSI) Treatment

    Policy of Reducing Multiple Births following In Vitro Fertilisation / Intracytoplasmic Injection (IVF/ICSI) Treatment Introduction When you really want to have a child, the idea of becoming pregnant with more than one baby as a result of your fertility treatment may sound ideal, especially if you have been waiting a long time. However, there are some significant risks associated with multiple pregnancies. Indeed, a multiple pregnancy is considered the single greatest health risk to both mother and child following IVF. Up until recently, about 1 in 4 IVF/ICSI pregnancies lead to the birth of twins or higher order multiple births (e.g. triplets). This means that after IVF/ICSI treatment, you are around 20 times more likely to have a multiple pregnancy than you would be if you conceived naturally. The reason for this high rate of multiple pregnancy is because, in most cases, more than one embryo is transferred during treatment. Research has also shown that women receiving fertility treatment are more likely to have identical twins (that is 2 babies derived from a single embryo), although this only accounts for a small proportion of the total number of twin pregnancies. In order to reduce the rates of multiple pregnancy, the Human Fertilisation and Embryology Authority (HFEA) has established regulations and targets, with which all fertility centres providing IVF/ICSI treatments must comply. What are the risks of a Multiple Pregnancy? A table comparing the risks of multiple and singleton pregnancies is available separately from this leaflet. Risks to the Mother All the risks of pregnancy and birth are significantly increased for women who are SDFC161 | Issue 5 | Author – David Chui | Authorised by – Jane Skelton 1 Publish Date: May 2020 | Review Due: May 2022 pregnant with more than one baby.
  • Effects of Clomiphene Citrate Plus Estradiol Or Progesterone On

    Effects of Clomiphene Citrate Plus Estradiol Or Progesterone On

    International Journal of Reproductive BioMedicine Volume 18, Issue no. 3, https://doi.org/10.18502/ijrm.v18i3.6718 Production and Hosting by Knowledge E Research Article Effects of clomiphene citrate plus estradiol or progesterone on endometrial ultrastructure: An RCT Robabeh Taheripanah1 M.D., Maryam Kabir-Salmani1, 2 Ph.D., Masoomeh Favayedi1 M.D., Marzieh Zamaniyan3, 4 M.D., Narges Malih5 M.D., Anahita Taheripanah6 B.Sc. 1Infertility and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 2Department of Biomaterials and Tissue Engineering, Stem Cell Division, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran. 3Department of Obstetrics and Gynecology, Infertility Center, Mazandaran University of Medical Sciences, Sari, Iran. 4Diabetes Research Center, Mazandaran University of Medical Sciences, Sari, Iran. 5Social Determinants of Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 6Department of Molecular and Cellular Sciences, Faculty of Advanced Sciences and Technology Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran. Corresponding Author: Marzieh Zamaniyan; Infertility Abstract Center, Imam Hospital, Amir Background: Pinopods concentrations in endometrial surface is a marker of Mazandarani Ave., Sari, Iran. implantation. Estradiol valerate (EV) was used to change the adverse effects of Postal Code: 4815659769 Clomiphene Citrate (CC) on the endometrium. Tel: (+98) 9113566650 Objective: The goal was to assess whether there is a significant difference in the Email: endometrial pinopods concentrations and other parameters after adding EV and [email protected] progesterone to higher doses of CC. Materials and Methods: In this prospective randomized clinical trial, a total of 30 Received 11 April 2018 women who did not respond to 100 mg of CC from February 2016 to June 2016 were Revised 6 October 2018 evaluated.
  • Progesterone Shifts the Pinopodes Expression of Mouse Endometrium to Pre-Implantation Time After Ovarian Hyperstimulation

    Progesterone Shifts the Pinopodes Expression of Mouse Endometrium to Pre-Implantation Time After Ovarian Hyperstimulation

    Iranian Journal of Reproductive Medicine Vol.1, No.1 pp. 20-23, 2003. Progesterone Shifts the Pinopodes Expression of Mouse Endometrium to Pre-Implantation Time After Ovarian Hyperstimulation Mojdeh Salehnia , Ph.D. Department of Anatomy, School of Medical Sciences, Tarbiat Modarres University, Tehran, Iran. Background: The aim of this study was to determine the correlation between ultrastructural studies for pinopodes expression after ovarian hyperstimulation and progesterone injection in mice. Materials and Methods: Adult NMRI mice were superovulated using human menopasual gonadotropic (hMG) and human chorionic gonadotropic (hCG) hormones; after that, daily injection of progesterone (1 mg/mouse) was performed. Animals were sacrificed by cervical dislocation 3.5 and 4.5 days after hCG injection. Tissues of uterine horns were obtained and processed for scanning (SEM) and transmission (TEM) electron microscopy studies. The pseudopregnant control samples were studied same as experimental groups. Results: The SEM and TEM observations showed that in control groups on 3.5 days of pregnancy, there were some pinopodes. All apical cell surfaces expressed these projections on the forth day. In progestrone-injected group, well developed pinopods were expressed 3.5 days after hCG injection and they were transformed to small projections on the fourth day following hCG injection. Also, the life span of pinopods was limited to a short time. At the TEM levels, the pinopods were seen as swelling process on the apical surface, which were more pronounced on day 3.5 of hCG injection in hyperstimulated and progestrone injection. Conclusion: The progestrone may cause premature expression of pinopodes and the implantation failure after ovarian induction may be due to these timing changes.
  • HCSD: the Human Cancer Secretome Database

    HCSD: the Human Cancer Secretome Database

    Downloaded from orbit.dtu.dk on: Sep 25, 2021 HCSD: the human cancer secretome database Feizi, Amir; Banaei-Esfahani, Amir; Nielsen, Jens Published in: Database: The Journal of Biological Databases and Curation Link to article, DOI: 10.1093/database/bav051 Publication date: 2015 Document Version Publisher's PDF, also known as Version of record Link back to DTU Orbit Citation (APA): Feizi, A., Banaei-Esfahani, A., & Nielsen, J. (2015). HCSD: the human cancer secretome database. Database: The Journal of Biological Databases and Curation, 2015, [bav051]. https://doi.org/10.1093/database/bav051 General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. Users may download and print one copy of any publication from the public portal for the purpose of private study or research. You may not further distribute the material or use it for any profit-making activity or commercial gain You may freely distribute the URL identifying the publication in the public portal If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Database, 2015, 1–8 doi: 10.1093/database/bav051 Database tool Database tool HCSD: the human cancer secretome database Amir Feizi1,2,AmirBanaei-Esfahani1 and Jens Nielsen1,2,3,* 1Novo Nordisk Foundation Center for Biosustainability, Department of Biology and Biological Engineering, Chalmers University of Technology, SE-41296 Go¨teborg, Sweden, 2Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Fremtidsvej 3, DK-2970 Downloaded from Hørsholm, Denmark and 3Novozymes A/S, Krogshoejvej 36, 2880 Bagsvaerd, Denmark *Corresponding author: Tel: þ46 31 772 3854; Fax: þ46 31 772 3801; Email: [email protected] Citation details: Feizi,A., Banaei-Esfahani,A.
  • Characterization of the Uterine Phenotype During the Peri-Implantation Period for LIF-Null, MF1 Strain Mice

    Characterization of the Uterine Phenotype During the Peri-Implantation Period for LIF-Null, MF1 Strain Mice

    Developmental Biology 281 (2005) 1–21 www.elsevier.com/locate/ydbio Characterization of the uterine phenotype during the peri-implantation period for LIF-null, MF1 strain mice A.A Fouladi-Nashtaa,1, C.J.P. Jonesb, N. Nijjar a, L. Mohamet a, A. Smithc, I. Chambersc, S.J. Kimber a,T aFaculty of Life Sciences, University of Manchester, 3.239 Stopford Building, Oxford Road, Manchester M13 9PT, UK bFaculty of Medical and Human Sciences, University of Manchester, Manchester M13 9PT, UK cCentre for Development in Stem Cell Biology, Institute for Stem Cell Research, University of Edinburgh, Edinburgh EH9 3QJ, UK Received for publication 9 August 2004, revised 20 January 2005, accepted 21 January 2005 Available online 9 March 2005 Abstract Leukemia inhibitory factor plays a major role in the uterus and in its absence embryos fail to implant. Our knowledge of the targets for LIF and the consequences of its absence is still very incomplete. In this study, we have examined the ultrastructure of the potential implantation site in LIF-null MF1 female mice compared to that of wild type animals. We also compared expression of proteins associated with implantation in luminal epithelium and stroma. Luminal epithelial cells (LE) of null animals failed to develop apical pinopods, had increased glycocalyx, and retained a columnar shape during the peri-implantation period. Stromal cells of LIF-null animals showed no evidence of decidual giant cell formation even by day 6 of pregnancy. A number of proteins normally expressed in decidualizing stroma did not increase in abundance in the LIF-null animals including desmin, tenascin, Cox-2, bone morphogenetic protein (BMP)-2 and -7, and Hoxa-10.
  • The Influence of Infertility and in Vitro Fertilization Treatment on Postpartum

    The Influence of Infertility and in Vitro Fertilization Treatment on Postpartum

    Linköping University Medical Dissertations No. 1554 The influence of infertility and in vitro fertilization treatment on postpartum and long-term mental health in women Josefin Vikström Eckevall Division of Obstetrics and Gynaecology Department of Clinical and Experimental Medicine Faculty of Medicine and Health Sciences Linköping University, Sweden © Josefin Vikström Eckevall The published articles have been reprinted with permission of the copyright holders. Printed by LiU-Tryck, Linköping 2016. ISBN - 978-91-7685-637-6 ISSN - 0345-0082 Table of contents Abstract 1 Sammanfattning 3 List of papers 9 Abbreviations 11 Introduction to the thesis 13 General introduction 13 Involuntary childlessness, infertility and psychological well-being 15 Infertility treatment outcome and psychological well-being 18 Voluntary childlessness 21 Infertility, IVF treatment and postpartum psychiatric disorders 21 Postpartum psychiatric disorders after infertility treatment 26 Long-term psychological consequences of infertility treatment 28 Psychological well-being and social support in middle and old age 30 Rationale and aims of the thesis 35 Aims of the individual studies 36 Material and methods 39 Study I-II 39 Population 39 Data sources 39 Study design 41 Data analyses 43 Study III 43 Population 45 Data sources 45 Study design 46 Data analyses 47 Study IV 47 Population 47 Data sources 48 Study design 49 Data analyses 50 Results 53 Study I 53 Study II 56 Study III 59 Study IV 61 General discussion and conclusions 67 Summary of principal findings 67 Methodological considerations 68 Principal findings in relation to other research 74 Limitations 88 Conclusions 91 Ethical considerations 93 Clinical implications 94 Future perspectives 95 Acknowledgements 97 References 99 Papers I-IV 111 To Björn and Karl Abstract Introduction: It is estimated that about 10-15% of couples suffer from infertility, i.e.